Aprea Therapeutics, Inc.
APREHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeAprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response. The company carries a $6.5M market cap, placing it firmly in the micro-cap category. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
Market Cap
$6.5M
Beta
1.63
P/E (TTM)
—
P/E (Fwd)
-1.28
EPS (TTM)
$-0.91
EPS (Fwd)
$-0.40
ROE
-46.2%
ROA
-27.7%
Cash
$41.2M
Total Debt
$0
Free CF
-$8.2M
52W Change
-61.3%
Annual Financials
Cash vs Debt
Where APRE stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, APRE finished 30.26% below its 150-day moving average ($0.76) and 31.17% below its 200-day moving average ($0.77). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is APRE overbought or oversold?
At the October 20, 2026 close, APRE's RSI(14) was 21.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Aprea Therapeutics, Inc. reports $41.2M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$8.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -46.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 1.63 means APRE is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing APRE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.